ABOS vs. FDMT, ALT, ALDX, FHTX, LRMR, CTNM, DMAC, AMRN, TECX, and KRRO
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include 4D Molecular Therapeutics (FDMT), Altimmune (ALT), Aldeyra Therapeutics (ALDX), Foghorn Therapeutics (FHTX), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), DiaMedica Therapeutics (DMAC), Amarin (AMRN), Tectonic Therapeutic (TECX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry.
Acumen Pharmaceuticals vs. Its Competitors
4D Molecular Therapeutics (NASDAQ:FDMT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.
In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 7 mentions for 4D Molecular Therapeutics and 2 mentions for Acumen Pharmaceuticals. 4D Molecular Therapeutics' average media sentiment score of 1.25 beat Acumen Pharmaceuticals' score of 0.95 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
4D Molecular Therapeutics has a beta of 2.86, indicating that its share price is 186% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.
4D Molecular Therapeutics currently has a consensus target price of $30.40, suggesting a potential upside of 346.40%. Acumen Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 430.30%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than 4D Molecular Therapeutics.
Acumen Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. 4D Molecular Therapeutics' return on equity of -40.15% beat Acumen Pharmaceuticals' return on equity.
Acumen Pharmaceuticals has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
4D Molecular Therapeutics beats Acumen Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ABOS) was last updated on 9/12/2025 by MarketBeat.com Staff
Free ABOS Stock Alerts